ClinicalTrials.gg
RecruitingNCT07397650FACILITATE-HFUpdated Aug 10, 2026

Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure

A Phase 4 interventional study of Finerenone Oral Tablet and Finerenone Placebo in Acute Heart Failure, sponsored by Juntendo University. Recruiting at 21 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Juntendo University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies testing finerenone in Heart Failure — 16 open to participants now, 17 under way, 8 of them phase 3. finerenone · Heart Failure.

Planned enrollment
8th of 23
550 · median 120
Started
2026
with 9 others
Phase 4
6 of 23
5 open now
Primary completion
2027-12
later than 9 of 16 live
Registered
17th of 23
by date
Lead sponsor
1 of 23
Juntendo University

Among the 23 studies testing finerenone in Heart Failure, this one is the 8th largest by planned enrollment, is one of 10 that started in 2026, is one of 6 in phase 4, reaches primary completion later than 9 of the 16 other live ones, and was the 17th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 23 studies testing finerenone in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing finerenone in Heart Failure, or all of them as a file.
02

Study summary

FACILITATE-HF is a multicenter, randomized, double-blind, placebo-controlled trial designed to determine whether initiation of finerenone during the early phase of hospitalization has beneficial effects in patients with AHF who have left ventricular ejection fraction 40% or more.

03

Conditions studied

  • Acute Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patients eligible for inclusion in this study meet all of the following criteria: \<br>Inclusion Criteria:

  1. Patients ≥18 years of age, male or female\<br>
  2. Current hospitalization with AHF requiring intravenous loop diuretics or vasodilators during the index admission\<br>
  3. Patients have to have at least one of new or worsening symptoms due to HF and one of new or worsening physical examination findings due to HF \<br> (i) symptom\<br> dyspnoea, decreased exercise tolerance, or fatigue\<br> (ii) physical examination\<br> peripheral edema, increasing abdominal distention or ascites, pulmonary rales/crackles/crepitations, increased jugular venous pressure and/or hepatojugular reflux, S3 gallop, or rapid weight gain\<br>
  4. Patients who are not hemodynamically unstable as defined by meeting the following criteria\<br>

    1. Systolic blood pressure ≥100 mmHg and no symptoms of hypotension within 6 hours prior to randomization\<br>
    2. No increase in intravenous diuretic dose or intravenous vasodilators within 6 hours prior to randomization with worsening HF symptom\<br>
    3. Without cardiogenic shock, no use of inotropes or vasopressors, no use of mechanical circulatory support, not requiring intubation after admission, and not expected to require inotropes, vasopressors, mechanical circulatory support or intubation during the index hospitalization\<br>
  5. NTproBNP ≥1500 pg/mL or BNP ≥375 pg/mL (For patients treated with ARNI in the previous 4 weeks prior to randomization, only NT-proBNP values should be used)\<br>
  6. Most recent ≥40% within the past 1 year \<br>
  7. Randomization within 24 hours after admission, and drug administration within 36 hours after admission \<br>
  8. Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol\<br>
  9. Signed informed consent must be obtained prior to participation in the study\<br>

Exclusion Criteria:

  1. Estimated (eGFR) \<25 mL/min/1.73m2 by CKD-EPI Creatinine Equation (2021) at screening\<br>
  2. Serum/plasma potassium >5.0 mmol/L at screening\<br>
  3. Patients who cannot receive oral treatment\<br>
  4. Use of eplerenone, spironolactone, esaxerenone or potassium-sparing diuretic within 30 days before randomization \<br>
  5. Known to the study intervention (active substance or )\<br>
  6. Systemic therapy with potent cytochrome P450 isoenzyme 3A4 () inhibitors or inducers within 7 days before randomization or is expected to be used during the study period (e.g. itraconazole, ritonavir, indinavir, cobicistat, clarithromycin).\<br>
  7. Participants who require treatment with more than one ACEI, ARB or angiotensin-receptor neprilysin inhibitor (ARNI) simultaneously\<br>
  8. Acute heart failure in which other diseases are the main cause of symptoms and signs (, anemia, etc.)\<br>
  9. Patients who are on dialysis including peritoneal dialysis or in whom the initiation of dialysis during the study period\<br>
  10. Pregnant or lactating female\<br>
  11. Acute coronary syndrome, pulmonary thromboembolism, stroke, or within 90 days before randomization.\<br>
  12. Have undergone the following therapeutic intervention within 30 days before randomization: cardiovascular surgery (e.g., coronary artery bypass grafting, surgery for valvular heart disease, transcatheter aortic valve implantation, percutaneous coronary intervention, percutaneous edge-to-edge mitral valve repair, and other types of surgery at the investigator's discretion) and implantation of an implantable defibrillator, or a cardiac resynchronization therapy defibrillator.\<br>
  13. Heart transplant recipients or patients listed for heart transplantation who are expected to undergo transplantation during the study, patients implanted with an implantable ventricular-assist device, patients expected to require an implantable ventricular-assist device during the study, and patients expected to switch to palliative care during the study.\<br>
  14. Coronary or valvular heart disease likely to require surgical or percutaneous intervention within the study period (there is no reason to exclude secondary mitral or tricuspid regurgitation due to reduced cardiac function, except for the absence of a plan to perform cardiac surgery or therapeutic catheterization)\<br>
  15. Secondary cardiomyopathy such as amyloidosis, cardiac sarcoidosis, hemochromatosis, Fabry's disease, chemotherapy induced cardiomyopathy, and muscular dystrophy. Heart failure due to takotsubo cardiomyopathy, obstructive hypertrophic cardiomyopathy, complex congenital heart disease (as determined by the investigator), pericardial constriction, right heart failure in absence of left-sided structural disease\<br>
  16. Acute cardiac structural abnormalities (e.g., acute mitral regurgitation due to ruptured chordae tendineae and infective endocarditis)\<br>
  17. Peripartum cardiomyopathy diagnosed within 6 months before randomization.\<br>
  18. Active myocarditis at randomization.\<br>
  19. Patients with symptomatic bradycardia or complete atrioventricular block who are being treated with temporary pacemaker implantation at the time of admission, or who are expected to require temporary or permanent pacemaker implantation in the future. Patients who have already been treated with permanent pacemaker implantation do not meet the exclusion criteria\<br>
  20. Presence of uncontrolled thyroid disease\<br>
  21. Addison's disease\<br>
  22. Hepatic insufficiency classified as C \<br>
  23. Patients with excessive alcohol intake (15+ drinks/week for men, 8+ drinks/week for women)\<br>
  24. Any other condition or therapy, which would make the participant unsuitable for this study and will not allow participation for the full planned study period (e.g. active or other condition limiting to less than 12 months)\<br>
  25. Patients with dementia. If a sub-investigator determines that confirmation of cognitive impairment is necessary, it must be verified that the Mini-Cog score is not less than 4.\<br>
  26. Participation in another interventional clinical study (e.g. phase 1 to 3 clinical studies) or treatment with another medicinal product within 30 days prior to randomization.Other conditions likely to interfere with the patient's safety or compliance with the protocol\<br>
  27. Patients deemed unsuitable by the principal investigator or sub investigator
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
550 participants (estimated)

Study arms

  • Experimental
    Finerenone

    Patients will be randomized 1:1 to either finerenone or placebo.

    Drug: Finerenone Oral Tablet

  • Placebo comparator
    Placebo

    Placebo tablets matching finerenone are administered orally

    Drug: Finerenone Placebo

Interventions

  • DrugFinerenoneStudies of FinerenoneFinerenone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    For participants with an eGFR ≤60 mL/min/1.73 m\^2: Starting dose is 10 mg OD and maximum dose 20 mg OD. For participants with an eGFR \>60 mL/min/1.73 m\^2: Starting dose is 20 mg OD and maximum dose 40 mg OD.

  • DrugFinerenone Placebo

    Placebo tablets matching finerenone are administered orally

06

What researchers measure

Primary outcomes

  1. A hierarchical composite endpoint of death and worsening heart failure

    A hierarchical composite endpoint consisting of death, worsening HF during hospitalization, HF rehospitalization, worsening HF after discharge requiring IV diuretic or sustained intensification of oral therapy, and change in N-terminal pro-B-type natriuretic peptide levels at 12 weeks as assessed using a win ratio

    Time frame: Up to 12 weeks

Secondary outcomes

  1. All-cause death

    Time frame: Up to 12 weeks

  2. Cardiovascular death

    Time frame: Up to 12 weeks

  3. Worsening HF during hospitalization

    Time frame: During hospitalization

  4. HF rehospitalization

    Time frame: Up to 12 weeks

  5. Worsening HF after discharge requiring IV diuretic or sustained intensification of oral therapy

    Time frame: Up to 12 weeks

  6. NT-proBNP change from baseline to 12 weeks

    Time frame: Up to 12 weeks

  7. Kansas City Cardiomyopathy Questionnaire - Total Symptom Score from baseline to 12 weeks

    Kansas City Cardiomyopathy Questionnaire - Total Symptom Score from baseline to 12 weeks. The scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations.

    Time frame: Up to 12 weeks

  8. Urine output from randomization to 48 hours

    Time frame: Up to 48 hours

  9. Change in patient dyspnea in the supine position assessed by a visual analogue scale from randomization to discharge and to 12 weeks

    Change in patient dyspnea in the supine position assessed by a visual analogue scale from randomization to discharge and to 12 weeks. The scores range from 0 to 100, with 100 being the best possible score.

    Time frame: Up to 12 weeks

  10. Symptomatic atrial fibrillation up to discharge and up to 12 weeks

    Time frame: Up to 12 weeks

07

Study locations

13 of 21 sites recruiting
  • Chita Peninsula General Medical Center
    Handa, Aichi-ken, Japan
    Recruiting
    • Susumu Suzuki · Contact
  • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
    Nagoya, Aichi-ken, Japan
    Not yet recruiting
    • Hideo Oishi · Contact
  • Nagoya University Hospital
    Nagoya, Aichi-ken, Japan
    Recruiting
    • Toru Kondo · Contact
  • National Center for Geriatrics and Gerontology
    Ōbu, Aichi-ken, Japan
    Not yet recruiting
    • Atsuya Shimizu · Contact
  • Toyota Kosei Hospital
    Toyota, Aichi-ken, Japan
    Recruiting
    • Tomoaki Haga · Contact
  • Ehime University Hospital
    Tōon, Ehime, Japan
    Recruiting
    • Osamu Yamaguchi · Contact
  • Japanese Red Cross Fukuoka Hospital
    Fukuoka, Fukuoka, Japan
    Not yet recruiting
    • Yasuhiro Oga · Contact
  • Iizuka Hospital
    Iizuka, Fukuoka, Japan
    Recruiting
    • Ryuichi Matsukawa · Contact
  • Gunma Prefectural Cardiovascular Center
    Maebashi, Gunma, Japan
    Not yet recruiting
    • Norimichi Koitabashi · Contact
  • Gunma University Hospital
    Maebashi, Gunma, Japan
    Recruiting
    • Masaru Obokata · Contact
  • NHO Takasaki General Medical Center
    Takasaki, Gunma, Japan
    Recruiting
    • Nobuaki Fukuda · Contact
  • Hokkaido Cardiovascular Hospital
    Sapporo, Hokkaido, Japan
    Recruiting
    • Kazunori Omote · Contact
  • Kitasato University Hospital
    Sagamihara, Kanagawa, Japan
    Not yet recruiting
    • Takeru Nabeta · Contact
  • Kindai University Hospital
    Sakai, Osaka, Japan
    Recruiting
    • Koichiro Matsumura · Contact
  • National Cerebral and Cardiovascular Center
    Suita, Osaka, Japan
    Not yet recruiting
    • Takeshi Kitai · Contact
  • The University of Osaka Hospital
    Suita, Osaka, Japan
    Recruiting
    • Yohei Sotomi · Contact
  • Saitama Medical Center
    Kawagoe, Saitama, Japan
    Not yet recruiting
    • Kentaro Jujo · Contact
  • Juntendo University Shizuoka Hospital
    Izunokuni, Shizuoka, Japan
    Not yet recruiting
    • Manabu Ogita · Contact
  • Chutoen General Medical Center
    Kakegawa, Shizuoka, Japan
    Recruiting
    • Shuji Morikawa · Contact
  • Osaka General Medical Center
    Osaka, Japan
    Recruiting
    • Mitsutoshi Asai · Contact
  • Juntendo University Hospital
    Tokyo, Japan
    Recruiting
    • Yuya Matsue · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2027, 19 months after the start.

Of 165 non-industry phase 4 interventional studies under Heart Failure, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 56. This study's planned 19 months is below that.

Counting every sponsor, half of 184 studies reached it within 31 months; a quarter within 21 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 9, 2026
StartActual
May 11, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Sep 30, 2028
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07397650
Lead sponsor
Juntendo University
Responsible party
Sponsor
First posted
Feb 9, 2026
Start date
May 11, 2026
Primary completion
Dec 2027 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Aug 10, 2026

Study contacts

Yuya Matsue, MD
Contact
yuya8950@gmail.com
81-3-3813-3111
Yuya Matsue, MD
principal investigator · Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion